Compare Quest Diagnostics Inc (DGX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Wix.Com Ltd — how do they compare? Quest Diagnostics Inc trades at $237.9 (market cap $26.21B), while Wix.Com Ltd trades at $65.83 (market cap $2.79B). The key difference: Quest Diagnostics Inc is far larger — about 9.4× Wix.Com Ltd's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| DGX | WIX | |
|---|---|---|
Market Cap | $26.21B | $2.79B |
Sector | Health | Technology |
52-Week High | $238.50 | $184.24 |
52-Week Low | $173.49 | $40.43 |
Enterprise Value | $31.97B | $3.87B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Wix trades at $62.43, up 3.7% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in three of the last four quarters, while revenue grew to $1.99B in 2025. The stock faces headwinds from a class action lawsuit following a Q1 2026 miss and a 27% price drop in May 2026.
The outlook is cautiously optimistic given Wall Street's $79.75 price target and 66% buy ratings, but litigation over financial disclosures and negative shareholder equity pose significant risks. Revenue growth remains a key catalyst, though profitability volatility requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
